Wang, Wei
Han, Dong
Cai, Qinbo http://orcid.org/0000-0001-5294-4319
Shen, Tao
Dong, Bingning
Lewis, Michael T.
Wang, Runsheng
Meng, Yanling
Zhou, Wolong
Yi, Ping
Creighton, Chad J. http://orcid.org/0000-0002-6090-703X
Moore, David D. http://orcid.org/0000-0002-5151-9748
Yang, Feng http://orcid.org/0000-0002-3401-5783
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (U54-CA224076, CA125123, CA125123)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health
R.P. Doherty Jr.–Welch Chair in Science (Q-0022).
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-17-1-0043)
Cancer Prevention and Research Institute of Texas (RP130651, RP200493)
Adrienne Helis Malvin Medical Research Foundation (MAPK4 as a Novel Therapeutic Target for Human Cancers)
Article History
Received: 12 January 2021
Accepted: 23 December 2021
First Online: 11 January 2022
Competing interests
: M.T.L. is founder and limited partner in StemMed Ltd, and founder and manager in StemMed Holdings, its general partner. He also holds an equity stake in Tvardi Therapeutics Inc. The other authors declare no competing interests.